Reata Pharmaceuticals (NASDAQ:RETA) PT Raised to $122.00

Reata Pharmaceuticals (NASDAQ:RETA – Free Report) had its target price increased by LADENBURG THALM/SH SH from $104.00 to $122.00 in a research report released on Thursday, The Fly reports. Several other analysts have also commented on the company. SVB Securities upgraded Reata Pharmaceuticals from a market perform rating to an outperform rating and increased their […]

Related Keywords

,Robertw Baird ,Manmeet Singh Soni ,Andrea Loewen ,Barclays ,Reata Pharmaceuticals Trading ,Reata Pharmaceuticals ,Citigroup ,Highmark Wealth Management ,Emerald Mutual Fund Advisers ,Emerald Advisers ,Reata Pharmaceuticals Inc ,Analyst Recommendations For Reata Pharmaceuticals ,Cantor Fitzgerald ,News Ratings For Reata Pharmaceuticals Daily ,Hedge Funds Weigh In On Reata Pharmaceuticals ,Free Report ,Moderate Buy ,Singh Soni ,Capital Management ,Mark Wealth Management ,Emerald Mutual Fund Advisers Trust ,Mutual Fund Advisers Trust ,Reata Pharmaceuticals Daily ,